Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nusinersen - Biogen/Ionis Pharmaceuticals

Drug Profile

Nusinersen - Biogen/Ionis Pharmaceuticals

Alternative Names: BIIB 058; IONIS-SMNRx; ISIS-396443; ISIS-SMNRx; Spinraza

Latest Information Update: 21 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation; Isis Pharmaceuticals
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action RNA interference; Survival of motor neuron 2 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Spinal muscular atrophy

Most Recent Events

  • 30 May 2024 Biogen completes the phase II/III DEVOTE trial in Spinal muscular atrophy (In children, In adolescents, In adults, In the elderly) in USA, Australia, Brazil, Canada, Chile, China, Colombia, Estonia, France, Greece, Germany, Hungary, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lebanon, Mexico, Netherlands, Poland, Russia, Saudi Arabia, Spain, Turkey, Taiwan and the UK (NCT04089566) (EudraCT2019-002663-10)
  • 27 Sep 2022 Launched for Spinal muscular atrophy (In adolescents, In children, In infants, In neonates, In adults) in Canada (Intrathecal)
  • 30 Aug 2022 The Canadian Agency for Drugs and Technologies in Health's (CADTH) announces their decision to not give reimbursement to adult patients with Spinal muscular atrophy (SMA) in Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top